Pharmacodynamics News and Research

RSS

Array Biopharma reports Q4 and full year 2009 financials

Array reported revenue of $5.5 million for the fourth quarter of fiscal 2009, compared to revenue of $6.1 million for the same period in fiscal 2008. Array invested $21.3 million in proprietary research and development for the quarter to advance its seven wholly-owned drugs in clinical development and select discovery programs.

10 Aug 2009

Alnylam and Tekmira to collaborate on RNAi therapeutics

Alnylam Pharmaceuticals, Inc. and Tekmira Pharmaceuticals Corporation announced today that they will jointly participate in a new research collaboration focused on the discovery of novel cationic lipids and lipid nanoparticles for the systemic delivery of RNAi therapeutics.

6 Aug 2009

Inhaled growth hormone safe for children deficient in this key protein

A multi-center clinical trial led by a Riley Hospital for Children endocrinologist has found that inhaled growth hormone (GH) is well tolerated by children with GH deficiency and that this easy-to-use method can, over a one-week period, safely deliver GH to the blood stream. In addition to having implications for those who need GH, this first pediatric study of administering it through the lungs may also help researchers interested in using this convenient method for effectively delivering other types of medications to children.

28 Jun 2009

Ardea Biosciences announces positive results from a phase 1 study of lead candidate for hyperuricemia and gout

Ardea Biosciences, Inc. has announced positive results from a Phase 1 study in normal, healthy volunteers of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, and a pilot Phase 2a proof-of-concept study in gout patients of RDEA594's prodrug, RDEA806 (RDEA806 is converted to RDEA594 in the body).

20 Apr 2009

SemBioSys Genetics announces clinical results with plant-produced insulin

SemBioSys Genetics Inc., specializing in the manufacture of high-value proteins and oils in plant seeds, today announced preliminary results of its first "in-man" clinical study of SBS-1000, a recombinant human insulin manufactured using its proprietary platform.

20 Mar 2009

Gilead initiates phase III trial of Elvitegravir

Gilead Sciences, Inc. has announced that it has begun enrolling patients in a Phase III clinical trial of its investigational antiretroviral agent elvitegravir (GS 9137), a novel oral integrase inhibitor that is being evaluated for the treatment of HIV-1 infection.

22 Jul 2008

ThromboGenics and BioInvent report positive results for anti-PlGF cancer therapeutic TB-403

ThromboGenics NV and co-development partner BioInvent International AB today reported that the results from the first Phase l study of novel anti-cancer agent TB-403 showed that it is safe and well tolerated, with pharmacokinetic properties enabling it to be developed for the treatment of cancer

3 Jun 2008

Breakthrough compound could lead to new class of antihypertensive drugs

University of Florida researchers have identified a drug compound that dramatically lowers blood pressure, improves heart function and - in a remarkable finding - prevents damage to the heart and kidneys in rats with persistent hypertension

1 May 2008

Inherited genes linked to toxicity of leukemia therapy

St. Jude investigators have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.

23 Jun 2007

Inherited variations in certain genes linked to toxicity of leukemia therapy

Investigators at St. Jude Children's Research Hospital have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.

15 May 2007

The science of sex and gender in human health

The National Institutes of Health (NIH) Office of Research on Women's Health (ORWH), in collaboration with the Food and Drug Administration (FDA) Office of Women's Health (OWH), have announces the launch of a new online course, "The Science of Sex and Gender in Human Health."

5 Jun 2006